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Abstract
Fibrosis, characterized by excessive collagen protein deposition, is a progressive disease that can 
fatally inhibit organ function. Prolonged exposure to pathogens or environmental toxicants such as 
asbestos can lead to chronic inflammatory responses associated with fibrosis. Significant exposure 
to amphibole asbestos has been reported in and around Libby, Montana due to local mining of 
asbestos-contaminated vermiculite. These exposures have been implicated in a unique disease 
etiology characterized predominantly by pleural disorders, including fibrosis. We recently reported 
the discovery of mesothelial cell autoantibodies (MCAAs) in the sera of Libby residents and 
demonstrated a positive and significant correlation with pleural disease; however, a mechanistic 
link was not determined. Here we demonstrate that MCAAs induce pleural mesothelial cells to 
produce a collagen matrix but do not affect production of the pro-inflammatory cytokine tumor 
growth factor-β. While autoantibodies commonly induce a pro-fibrotic state by inducing 
epithelial–mesenchymal transition (EMT) of target cells, we found no evidence supporting EMT 
in cells exposed to MCAA positive human sera. Although implicated in other models of 
pulmonary fibrosis, activity of the protein SPARC (secreted protein, acidic and rich in cysteine) 
did not affect MCAA-induced collagen deposition. However, matrix formation was dependent on 
matrix metalloproteinase (MMP) activity, and we noted increased expression of MMP-8 and -9 in 
supernatants of mesothelial cells incubated with MCAA positive sera compared to control. These 
data suggest a mechanism by which MCAA binding leads to increased collagen deposition 
through altering MMP expression and provides an important mechanistic link between MCAAs 
and asbestos-related, autoimmune-induced pleural fibrosis.
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Asbestos exposure has long been linked with increased incidence of lung abnormalities 
including fibrosis, pleural plaques and respiratory tract cancers (Kamp, 2009). However, 
evidence suggests that in addition to these traditional asbestos-related diseases (ARDs), 
asbestos may also trigger autoimmune responses, as evidenced by circulating auto-
antibodies and immune complexes in asbestos workers (Lange, 1980; Nigam et al., 1993). A 
high prevalence of systemic autoimmune disease has also been reported in Libby, Montana 
(Noonan et al., 2006; Pfau et al., 2005) where local mining activities resulted in wide-spread 
occupational and environmental exposure to amphibole asbestos between 1924 and 1990 
(Bandli & Gunter, 2006; Whitehouse et al., 2008). These exposures have also been 
associated with high incidences of pleural changes and non-malignant respiratory disease 
morbidity, coupled with decreased pulmonary function due to progressive fibrotic disease 
(Larson et al., 2010; Peipins et al., 2003; Rohs et al., 2008; Sullivan, 2007; Whitehouse, 
2004).
Recent studies support a role for pathogenic autoantibodies in a number of fibrotic and 
vascular disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) 
and systemic scleroderma (SSc) (Chizzolini et al., 2002; Del Papa et al., 1994; Ihn et al., 
2000; Renaudineau et al., 1999). Interestingly, exposure to Libby amphibole (LA) has been 
linked to increased risk of developing one of these three systemic autoimmune disorders 
(Noonan et al., 2006), and area clinicians caring for Libby residents have noted an increased 
disease progression in patients presenting with both pulmonary fibrosis and autoimmune 
symptoms [manuscript in preparation]. Thus, the evidence suggests an autoimmune 
component to Libby ARD, as similarly noted in studies of other asbestos-exposed groups 
(Tamura et al., 1993, 1996).
We recently reported on the presence of mesothelial cell autoantibodies (MCAA) in the 
serum of LA-exposed subjects in which MCAA presence was positively and significantly (p 
=0.044) correlated with radiographic changes indicative of pleural, but not interstitial, 
disease (Marchand et al., 2012). Thus, we suspected a pathogenic role of these MCAAs in 
development of asbestos-related pleural fibrosis. Discovery of a pathogenic role for these 
autoantibodies may potentially provide a therapeutic target for pleural fibrosis in individuals 
where these autoantibodies are present.
Mesothelial cells have long been reported to deposit extracellular matrices in vitro (Harvey 
& Amlot, 1983) and in vivo (Davila & Crouch, 1993; Nasreen et al., 2009; Wynn, 2008) 
following pleural injury and exposure to pro-fibrotic and inflammatory cytokines. Such 
cytokines may induce pleural cell differentiation to a myofibroblast-like phenotype (Guarino 
et al., 2009; Parsons et al., 2007; Zavadil & Bottinger, 2005) characterized by smooth 
muscle α-actin (SMA) expression and increased secretion of collagen proteins type I and III 
(Hinz et al., 2007; Phan, 2002; Zhang et al., 1994). While these processes are part of the 
normal response to tissue injury and wound-healing, they may become pathogenic upon 
disruption of collagen metabolism homeostasis. Autoantibodies to fibroblast cells have been 
shown to increase collagen accumulation by inducing cell differentiation to a myofibroblast 
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cell (Pfau et al., 2011) or by directly stimulating signaling cascades leading to an up-
regulation of collagen gene expression (Baroni et al., 2006). We hypothesized that MCAA 
binding might similarly drive mesothelial cell differentiation and collagen protein synthesis.
Alternatively, decreased collagen degradation and turnover can result in a net increase in 
extracellular protein accumulation. Following collagen synthesis and secretion, proteins are 
cleaved by collagenolytic enzymes to produce mature proteins. Multiple types of collagen 
proteinases have been implicated in the development of pulmonary fibrosis. We examined 
the potential contribution of such proteinases to MCAA-associated fibrosis. The 
matricellular glycoprotein SPARC (secreted protein acidic and rich in cysteine) is expressed 
during development and tissue remodeling and repair (Sage et al., 1989a,b) and mediates 
pro-collagen processing and assembly into fibrils (Harris et al., 2011; Rentz et al., 2007). 
Additionally, SPARC has been implicated in collagen protein expression and accumulation 
in bleomycin-induced pulmonary fibrosis (Strandjord et al., 1999; Wang et al., 2010) and 
following asbestos exposure (Pershouse et al., 2009; Wang et al., 2010). It is also suspected 
that SPARC plays a role as a scavenger chaperone protein responsible for collagen turn-over 
(Chlenski et al., 2011; Martinek et al., 2007). Thus, we considered the possibility that 
MCAA binding affects endogenous SPARC expression, potentially affecting collagen 
accumulation.
Additionally, we considered that alterations in expression of matrix metalloproteinases 
(MMPs) could contribute to MCAA-associated fibrosis development. Several members of 
the MMP zinc-dependent endoproteinase family display activity toward collagen type I, 
including MMP 1, 2, 8, 9 and 13. Multiple MMPs have been implicated in pulmonary and 
interstitial lung fibrosis, including idiopathic pulmonary fibrosis and silicosis (Dancer et al., 
2011; Scabilloni et al., 2005), as well as in asbestos-associated inflammation and fibrosis 
(Tan et al., 2006). Exposure to chrysotile asbestos was shown to increase MMP-8 release 
from neutrophils in vitro (Hedenborg et al., 1990) while exposure to the more fibrogenic 
asbestos crocidolite increased MMP-2 and -9 expression in vivo (Tan et al., 2006). MMP-8 
deficiency was shown to be protective in a bleomycin model of pulmonary injury, potentially 
through decreased processing of the anti-fibrotic cytokine IL-10 (Garcia-Prieto et al., 2010). 
Based on this evidence, we examined the effect of MCAA binding on MMP activity and 
expression in mesothelial cell supernatants.
Here, we report findings indicating that MCAAs induce pleural mesothelial cells to deposit 
extracellular collagen type I proteins in an MMP-dependent fashion, potentially by 
modulating MMP expression. Additionally, we demonstrate that MCAAs do not elicit 
mesothelial cell differentiation to a myofibroblast-like cell, as has been extensively reported 
for fibroblast-mediated collagen deposition. Further, this collagen deposition was not 
dependent on TGF-β or SPARC activity, as reported for other models of asbestos-associated 
fibrosis. Thus, the MCAAs seem to promote collagen deposition by unique mechanisms, 
which likely work in parallel or conjunction with other reported mechanisms of fibrosis, 
including asbestos-induced cell damage and chronic inflammation. The ability of an 
autoimmune and inflammatory response to cooperate in exacerbating fibrotic processes is a 
novel and important consideration for fibrotic disorders with unexplained etiology.
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Non-malignant, transformed human mesothelial cells, MeT-5A (ATCC, Manassas, VA) were 
grown in RPMI medium (CellGro Mediatec, Manassas, VA) supplemented with 5% fetal 
bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA) and antibiotics. Cells were 
maintained at 37 °C and 5% CO2.
Human serum samples and IgG clearance
Serum samples were collected by the Center for Asbestos Related Disease (CARD) in 
Libby, Montana in accordance with Idaho State University IRB project approval #3292MOD 
and was stored at −80 °C until needed. Samples previously identified as MCAA positive 
(+ive) or negative (−ive) were pooled (Marchand et al., 2012) and small aliquots stored at 
−20 °C. Sera cleared of IgG antibodies were used as negative controls. Sera were cleared 
using Protein A Agarose Beads (Thermo Scientific, Rockford, IL) according to 
manufacturer’s instructions. IgG removal was confirmed by running sera on a 12% Bis–Tris 
gel (Novex, Life Technologies, Carlsbad, CA) and staining with GelCode Blue Stain 
Reagent (Thermo Scientific) and checking for lack of bands corresponding to the molecular 
weight of IgG heavy and light chains (50 and 25 kDa).
MCAA cell binding assay
A cell-based ELISA was performed as previously described (Marchand et al., 2012) to 
compare the binding efficacy of pooled sera to individual samples. Briefly, MeT-5A cells 
were seeded at confluency on 96 well plates, attached overnight and fixed in 1% 
paraformaldehyde. Following washing with PBS-Tween (0.05%), cells were blocked with 
5% dried milk/ PBS and then exposed to pooled sera previously identified as MCAA 
positive or negative or cleared sera in 3% BSA/PBS (1:100). Following a 2-h incubation 
with primary antibody, cells were washed and blocked a second time. The secondary 
antibody HRP-conjugated goat anti-human IgG (Jackson ImmunoResearch, West Grove, 
PA) was applied at a dilution of 1:1000 in 3% BSA/PBS and incubated for 1 h. Excess 
antibody was removed and plates developed using TMB reagent (Thermo Scientific) 
followed by 30 μl 1 M HCl. Plates were analyzed at 450 nm on a microtiter plate reader 
(BioTek Instruments, Winooski, VT). Non-specific secondary antibody binding was 
corrected for on a plate-to-plate basis by subtracting the mean optical density (OD) for the 
secondary antibody-only control wells from the mean OD of each sample.
Cell-based ELISA for detecting collagen and SPARC
Collagen and SPARC proteins were detected using cell-based ELISA. Cells were seeded as 
above and then exposed to sera, diluted 1:50 in FBS-free RPMI. Following a 4-d incubation 
at 37 °C, supernatant was removed and cells were fixed, washed and blocked as described 
earlier. Primary antibody diluted in 3% BSA/PBS was applied for 2 h and consisted of 
mouse monoclonal anti-collagen I (AbCam), 1:2000, or rabbit polyclonal IgG anti-SPARC, 
H-90 (Santa Cruz Biotechnology, Santa Cruz, CA), 1:200. Following another round of 
Serve et al. Page 4













washing and blocking, the HRP-conjugated secondary antibodies (1:1000) were applied for 
1 h. Plates were then washed, developed and analyzed as described earlier.
A cell-based ELISA was also used to assess the contribution of endogenous SPARC and 
MMPs to collagen matrix formation. Cells were treated with sera as above, with or without 
the addition of SPARC inhibitor (anti-SPARC antibody, 1 μg/mL) on day 1 or the MMP 
inhibitor, EDTA (5 mM), on day 3. Collagen protein deposition was determined using the 
ELISA protocol above.
Soluble collagen assay
The concentrations of soluble collagen proteins in supernatant of cells incubated for 4 days 
with MCAA +ive or −ive sera (1:50 in FBS-free RPMI) were determined using a Sircol 
Collagen Assay (Biocolor, Carrickfergus, North Ireland) according to the manufacturer’s 
instructions. Following collagen extraction from supernatants, samples were analyzed using 
a microtiter plate reader (BioTek Instruments) with absorbances measured at 562 nm. Mean 
OD of samples were normalized to reagent blank, and collagen concentrations (μg/ mL) 
were determined by comparing sample absorbance against the standard curve. All samples 
were read in duplicate.
Additionally, detergent soluble fractions of collagen were collected by lysing cells in buffer 
containing 0.2% deoxycholic acid and incubated on a rotor at 4 °C overnight. Cell debris 
was removed by centrifugation and the supernatants assayed for soluble collagen proteins as 
above.
Smooth muscle α-actin expression
Cells were plated at near confluency and attached overnight. Cells were then treated with 
MCAA +ive or −ive sera (1:50), normal human sera (1:50), or TGF-β (2 ng/mL) as a 
positive control, in FBS-free RPMI, 100 μl final volume. After 4 d, medium was removed 
and cells were released from plates by 5-min treatment with trypsin/EDTA (Mediatech, 
Inc.). Cells were pelleted by centrifugation, washed once with 3% BSA/ PBS, fixed in 
Fixation Buffer (BD Pharmingen, BD Biosciences, San Jose, CA) for 20 min and then 
washed twice in 1 × Perm/Wash buffer (BD Pharmingen). The cells were stained for smooth 
muscle α-actin (SMA) by adding 1 μg of mouse monoclonal antibody (Thermo Scientific) 
per 1 × 106 cells. Following 15-min incubation, cells were washed twice and incubated for 
15 min with the secondary FITC-conjugated goat anti-mouse antibody (1:1000). Excess 
antibody was removed by washing and cells were resuspended in PBS and analyzed on a 
FACS Calibur flow cytometer (BD Biosciences).
Samples were analyzed by gating on live cells and mean fluorescence intensity measured 
against background fluorescence of control cells stained with secondary Ab only.
Cytokine bead flex set analysis of TGF-β
TGF-β1 concentrations in human sera samples and cell supernatants were determined using 
a human TGF-β1 single plex cytokine bead flex set kit (BD Biosciences, San Diego, CA). 
Supernatants were collected from cells treated for 4 d with MCAA +ive or −ive sera, normal 
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human serum, or media only. Latent TGF-β was activated in supernatants and serum 
samples by acidification (pH<3.0) for 10 min followed by neutralization (pH 7.2–7.6) prior 
to testing for cytokine concentrations. Activated samples were then incubated with prepared 
flex set capture beads then incubated with prepared PE detection reagent according to 
manufacturer’s instructions. Samples were analyzed on a FACS Calibur flow cytometer and 
analyzed using CellQuest software (BD Biosciences, San Jose, CA). Total TGF-β1 
concentrations were determined by comparing geometric means of samples to a standard 
curve.
Immunoblots
Cells were seeded at near confluency and attached overnight. MCAA +ive or −ive sera or 
cleared serum was then added at 1:50 dilution in FBS-free RPMI and incubated for 4 d at 
37 °C. Supernatants were collected and stored at −20 °C until use. Cells were collected via 
scraping and lysed in buffer (1% Triton, 0.2% Deoxycholic Acid, 50 mM Tris, 150 mM 
NaCl), centrifuged to remove cell debris and stored at −20 °C until use.
Total protein concentrations were determined using a BCA Protein Assay Kit (Thermo 
Scientific, Waltham, MA). Supernatants or lysates were then were mixed with 5 × SDS 
loading buffer containing β-mercaptoethanol and heated to 100 °C for 5–10 min. Proteins 
were separated on a 12% Bis–Tris gel (Novex, Life Technologies, Carlsbad, CA) in 1 × 
NuPAGE MOPS SDS Running Buffer (Invitrogen, Carlsbad, CA) for 1.5 h at 150 V and 
transferred to a PVDF membrane at 30 V for 45 min in 1×NuPAGE Transfer Buffer 
(Invitrogen). Membranes were air dried, briefly re-wetted in methanol, washed twice with 
PBS and blocked in 5% milk/ PBS for 1 h at room temperature.
The primary antibody diluted 1:200 in 3% BSA/PBS was applied overnight at room 
temperature and consisted of rabbit polyclonal IgG antibody anti-SPARC or anti-MMP-8 
(Santa Cruz Biotechnology). Membranes were washed twice in PBS-T (0.05%), blocked and 
incubated for 1 h at room temperature with secondary antibody, HRP conjugated goat anti-
rabbit (1:1000). Excess antibody was removed by washing and the blot developed with TMB 
reagent (Thermo Scientific). Bands were visualized on a VersDoc Imaging System with 
Quantity One software (version 4.6.5, BioRad). Densitometry was determined using ImageJ 
software.
Collagenase zymography
Zymogen assay was used to assess the activity of collagenases in supernatants of cells 
exposed to MCAAs. Supernatants were collected from cells incubated for 4 days with 
MCAA +ive or −ive sera, normal human serum, or medium only. About 10 μg total protein 
was loaded onto a 10% acrylamide gel impregnated with type I collagen (Sigma Aldrich) 
and run under non-reducing conditions. Proteins were separated at 65 V for 1 h. Gels were 
washed for 1 h at room temperature with shaking in activation solution (50 mM Tris, pH 7.4, 
5 mM CaCl2, 1 μM ZnCl2) containing 2.5% Triton-X. Gels were then rinsed briefly in DI 
H2O and incubated for 18 h at 37 °C in activation buffer. Gels were then stained in 
Coomassie Blue stain for 30 min and destained in 30% EtOH/10% AcOH overnight. 
Staining was stopped in 2% AcOH and bands visualized on a VersDoc Imaging System with 
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Quantity One software (version 4.6.5, BioRad). Collagenase from Clostridium histolyticum, 
200 pg (Sigma-Aldrich) was used as a positive control.
Statistical analyses
One-way or two-way ANOVAs were performed using SigmaPlot version 11.0 (Systat 
Software, San Jose, CA). Statistical significance was defined as a p values ≤ 0.05. Data are 
graphed with error bars indicating either SEM or SD.
Results
Sera of Libby residents were previously identified as MCAA positive (+ive) or negative 
(−ive) using a cell-based ELISA to assess binding to cultured pleural human mesothelial 
cells (Marchand et al., 2012). We randomly pooled MCAA +ive and −ive samples and 
compared the binding ability between pooled and individual samples. Additionally, binding 
of pooled MCAA +ive and −ive samples were compared to binding ability of normal human 
sera (NHS) obtained from a donor with no known asbestos exposure and to sera from which 
IgG was removed (Cleared Sera). We determined that individual and pooled samples did not 
significantly vary in their binding ability for either MCAA +ive (p =0.427) or −ive sera (p 
=0.422), indicating that pooled samples are appropriate for use in our experimental model 
(Figure 1A). However, MCAA +ive sera demonstrated significantly higher binding 
(p<0.001) compared with MCAA −ive sera and NHS, suggesting a lack of antibody against 
mesothelial cells in the latter samples (Figure 1B). Binding was lost upon clearance of IgG 
from samples, indicating that MCAAs are IgG type antibodies.
To determine if MCAA binding induces collagen deposition, cells were incubated with 
pooled sera for 4 d and collagen I measured using a cell-based ELISA. Cells exposed to 
MCAA +ive sera demonstrated a significant increase in collagen detection compared to 
those incubated with MCAA −ive or NHS (p<0.001). Clearing sera of IgG antibodies 
reduced collagen presence to background levels (Figure 2A), suggesting that the MCAAs 
specifically increased collagen detection. Additionally, collagen deposition did not 
significantly differ between cells treated with pooled sera or individual serum samples (p 
=0.277), thus further validating the use of pooled sera for MCAA analyses (Figure 2B).
Extracellular collagen deposition is carefully regulated by a balance of collagen synthesis 
and catabolism. Disruption of these processes may result in a net accumulation of collagen 
proteins and progression of fibrosis (Wynn, 2007). Cellular activation to express a 
myofibroblast-like phenotype has been reported following cell exposure to pro-fibrotic 
cytokines (Hinz et al., 2007) or autoantibody binding (Pfau et al., 2011). We hypothesized 
that MCAA binding would promote mesothelial cell differentiation by activating an 
intracellular signaling cascade leading to expression of myofibroblast genes following cell 
binding (Pfau et al., 2011). We previously showed that MCAAs bind to the cell surface of 
cultured mesothelial cells (Marchand et al., 2012) and that asbestos-associated auto-antibody 
binding activates signal transduction pathways and mesenchymal transition in cultured 
fibroblast cells (Pfau et al., 2011). Mesothelial cell differentiation was assessed by using 
flow cytometry to measure the intracellular expression of smooth muscle α-actin (SMA) in 
the mesothelial cell. Since SMA is a myofibroblast marker, increased expression indicates 
Serve et al. Page 7













cellular differentiation. However, flow cytometric analysis of SMA expression revealed no 
significant differences between cells incubated with MCAA +ive or −ive sera, indicated by 
overlapping plots, although SMA expression did increase in cells exposed directly to the 
potent pro-fibrogenic cytokine TGF-β (5 ng/μL) used as a positive control (Figure 3A). 
Interestingly, exposure to sera of asbestos-exposed subjects did increase SMA expression 
compared to NHS, just not to the extent observed in positive control cells. We suspected that 
this increase might be a result of TGF-β present in the sera. Using a cytokine bead array 
(BD Biosciences), we measured TGF-β concentrations in the pooled MCAA +ive and −ive 
sera samples. Approximately 35 ng/μl of TGF-β was detected in these samples, with no 
statistical difference between them (Figure 3B). Additionally, we examined the cell 
supernatants to ensure that exposure to sera of asbestos-exposed subjects did not induce 
mesothelial cell production of TGF-β. We detected ~0.7 ng/μl of TGF-β in the supernatants 
(Figure 3C). Since sera was added to cells at a 1:50 dilution, the TGF-β detected in 
supernatants is likely solely from the sera and not produced from the mesothelial cells. 
Additionally, even at this low TGF-β concentration, we would expect to see a slight effect on 
SMA expression (May et al., 1988).
Since mesenchymal cells are characterized by increased collagen synthesis, we further 
established the lack of mesenchymal transition by comparing concentrations of newly 
synthesized collagens in supernatants of cells exposed to MCAA +ive or −ive sera. No 
differences in collagen concentrations were detected following exposure to any human sera 
as determined by Sircol Soluble Collagen Assay (Figure 3D). Taken together, these data 
confirmed that exposure to MCAA +ive sera did not increase collagen deposition by 
inducing a phenotypic change in these cells.
Since MCAA binding does not induce collagen synthesis or a mesenchymal transition, we 
hypothesized that MCAA binding might affect the expression or activity of proteolytic 
enzymes that function in collagen catabolism. Several such enzymes are associated with 
fibrosis and altered extracellular collagen metabolism, including SPARC and the MMP 
family of enzymes.
Endogenous SPARC expression was detected in supernatants of pleural mesothelial cells, 
but protein levels did not change following cell exposure to MCAA +ive or −ive sera (Figure 
4A and B). Using a cell-based ELISA, SPARC detection significantly increased in cells 
exposed to MCAA +ive sera (Figure 4C). To determine if SPARC affects MCAA-induced 
collagen production or merely associates with collagen following its deposition, we used a 
neutralizing antibody to inhibit SPARC activity (Goldblum et al., 1994) and then examined 
collagen I deposition. Inhibition of SPARC did not significantly affect collagen deposition 
(Figure 4D), indicating that SPARC does not significantly contribute to MCAA-induced 
collagen deposition in vitro.
In order to determine if MMP activity contributes to MCAA-induced collagen deposition, 
we detected collagen I as described earlier with or without the addition of the non-specific 
MMP inhibitor EDTA (5 mM). EDTA significantly reduced collagen deposition in cells 
incubated with MCAA +ive sera but not in MCAA −ive sera or NHS (Figure 5A). Collagen 
zymography was used to determine which MMPs were present in supernatants of cells 
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incubated with human sera and active toward type I collagen. The zymogen assay revealed 
double band at ~98 and 92 kDa corresponding to reported molecular weights of pro and 
active MMP-9, respectively (Figure 5B). A single band was also detected at ~58 kDa, which 
corresponded to the active form of MMP-8 (Figure 5B). Taken together, these data suggest a 
role of MMPs in MCAA-induced collagen matrix deposition in vitro, potentially through 
activity of MMP-8 or MMP-9. Immunoblot analysis confirmed the presence of MMP-8 
(Figure 5C) and densitometric analysis (Figure 5D) revealed a significant increase in 
MMP-8 expression by cells exposed to MCAA +ive sera compared to NHS exposure (p ≤ 
0.01). Cell exposure to MCAA −ive sera also resulted in increased MMP-8 expression, 
although this increase was not significant (p =0.085). Attempts to detect MMP-9 via 
immunoblot analysis were unsuccessful.
Discussion
Fibrotic diseases are characterized by excessive collagen deposition resulting in decreased 
organ function and eventual organ failure. Increasing evidence implicates a role for 
autoantibodies in driving collagen accumulation (Chizzolini et al., 2002; Ihn et al., 2000; 
Renaudineau et al., 1999), often by inducing cells to undergo a phenotypic change to a 
myofibroblast-like cell. Such a mesenchymal transition is has been described for epithelial 
(Willis et al., 2005), endothelial (Hashimoto et al., 2010; Piera-Velazquez et al., 2011), 
fibroblastic (Pfau et al., 2011; Zhang et al., 1996) and mesothelial cells (Liu et al., 2008; 
Nasreen et al., 2009). Alternatively, autoantibody binding stimulates production of pro-
fibrogenic or inflammatory cytokines (Guo et al., 2004) which may in turn act in autocrine 
or paracrine fashions to further exacerbate chronic inflammatory conditions attributed to 
fibrosis progression.
Pleural fibrosis arising from prolonged exposure to LA asbestos is a relentlessly progressive 
disease (Whitehouse, 2004) associated with chronic inflammation and increased serum 
autoantibodies to fibroblast and mesothelial cells (Marchand et al., 2012; Pfau et al., 2011). 
While the role of fibroblasts in regulating pleural fibrosis is better characterized than that of 
mesothelial cells (Chizzolini et al., 2002; Fineschi et al., 2008; Gabrielli et al., 2007; 
Kuwahara et al., 1994; Pfau et al., 2011; Phan, 2008), evidence suggests that mesothelial 
cells are also crucial mediators of pleural disease progression (DavilaandCrouch, 1993; 
HarveyandAmlot, 1983; Nasreen et al., 2009). Harvey and Amlot demonstrated in 1983 that 
mesothelial cells obtained from pleural effusions were capable of depositing type I and III 
collagens in vitro, implicating a role for mesothelial cells in pleural fibrosis (Harvey & 
Amlot, 1983). Additionally, several groups have demonstrated that mesothelial cells are 
important sources of cytokines and chemokines within the pleura, thus providing a means of 
recruiting fibrogenic and immunogenic cells (Antony et al., 1995; Boylan et al., 1992; 
Griffith et al., 1994; Kuwahara et al., 1994). It was also recently suggested that mesothelial 
cells themselves are potentially fibrogenic following exposure to the pro-inflammatory 
growth factor TGF-β1 (Nasreen et al., 2009). Thus, our investigations focused on the role of 
mesothelial cell autoantibodies (MCAAs) in inducing fibrogenic changes within cultured 
human pleural mesothelial cells.
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Our results demonstrated increased detection of extracellular collagen I proteins in cells 
exposed to MCAA +ive sera compared to MCAA −ive sera or NHS. Clearance of IgG from 
the sera eliminated MCAA binding as well as collagen detection, thus implicating a role for 
MCAA binding in driving the observed collagen production. We additionally screened the 
sera of LA-exposed subjects for anti-fibroblast antibodies, but no cross-reactivity was 
detected, indicating that MCAA binding was specific to mesothelial cells.
Interestingly, our results suggest that MCAA binding induced collagen production in the 
absence of a mesothelial-mesenchymal transition. This finding counters the currently 
accepted model of fibrosis development in which collagen-producing cells are either 
myofibroblasts recruited to the area via chemokine release or are local cells that have 
undergone a mesenchymal transition. Here, we suggest an alternative in which 
autoantibodies themselves induce target cells to deposit extracellular matrix proteins.
Since MCAAs do not affect mesothelial cell phenotypes, we considered the possibility that 
binding directly stimulates collagen I synthesis or processing. Collagen I is a hetero-trimer 
composed of two α1(I) and one α2(I) chains. These proteins are encoded by the genes, 
COL1A1 and COL1A2, respectively, and are translated into immature pro-collagen peptides. 
Collagenolytic proteins cleave pro-peptides from both the N- and C-termini, leaving the 
processed proteins to arrange themselves into long, thin fibrils. Fibril maturation into strong 
collagen I matrices occurs upon fibril cross-linking (Cooper, 1970; Siegel, 1976). Since the 
Sircol Soluble Collagen Assay does not detect cross-linked collagen fibers, we used this 
assay to compare the concentrations of newly synthesized collagen in supernatants of cells 
exposed to MCAA +ive or −ive sera. No differences were detected between exposure 
groups, suggesting that MCAAs likely do not directly stimulate collagen synthesis and 
confirming the lack of MCAA-associated mesothelial–mesenchymal transition.
A key regulator of collagen production is TGF-β, which was detected in sera of the asbestos-
exposed subjects. However, detection of TGF-β does not preclude the possibility that 
another serum component was responsible for the slight increase in collagen synthesis 
detected. Since asbestos fibers themselves are potent inducers of inflammation and 
fibrogenic responses, it is likely that these responses would work synergistically with 
MCAAs to further promote fibrosis development in vivo. Additionally, no increases in the 
fibrogenic cytokine TGF-β were detected in supernatants of cells exposed to MCAA +ive 
sera. Thus, MCAA binding does not induce secretion of this cytokine. While TGF-β clearly 
plays a crucial role in driving fibrosis development in vivo, this cytokine was not responsible 
for driving collagen production by mesothelial cells in vitro. However, since asbestos 
exposure increases TGF-β production (Dai et al., 1998; Liu & Brody, 2001; Liu et al., 1996), 
it is likely that following asbestos inhalation, MCAAs and TGF-β work synergistically to 
further enhance fibrosis development beyond the effects of either protein alone.
Since collagen processing is a key regulatory event leading to production of mature collagen 
fibers and formation of the collagen matrices observed in fibrotic diseases, we examined the 
effect of MCAA binding on the expression and activity of several collagenolytic proteins. 
SPARC is a matricellular protein associated with exacerbation of fibrosis in asbestos and 
bleomycin exposure models (Pershouse et al., 2009; Strandjord et al., 1999; Wang et al., 
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2010). While SPARC detection increased in cells exposed to MCAA +ive sera compared to 
controls, MCAA exposure did not affect protein expression by mesothelial cells.
Since SPARC associates with extracellular collagen matrices (Iruela-Arispe et al., 1996), it 
is likely that the increased detection of SPARC merely confirms its association with the 
collagen produced by MCAA-exposed cells. The pattern of SPARC detection in our assays 
suggests that the collagen I proteins detected by ELISA are mature fibers and not pro-
collagen proteins. It has been demonstrated that collagen I precursors are bound to cell 
surfaces and released, and subsequently incorporated into a collagen matrix, following 
cleavage by SPARC (Harris et al., 2011; Rentz et al., 2007). Thus, if the ELISA analyses 
were merely detecting collagen precursors bound to cell surfaces, we would expect that 
SPARC inhibition would also inhibit release of pro-collagen, thus increasing collagen 
detection via ELISA. Conversely, SPARC inhibition would decrease the amount of soluble 
collagen detected in cell supernatants. However, SPARC inhibition did not significantly alter 
collagen detection by either ELISA or Sircol assay. Thus, we suspect that we are not merely 
detecting cell-bound collagen precursor proteins but mature collagen fibrils following cell 
stimulation with MCAA +ive sera. Additionally, the collagen fractions we detect via ELISA 
were detergent insoluble, thus indicating a mature matrix structure.
To further examine the possibility that MCAA binding alters expression or activity of 
collagenolytic proteins, thereby increasing collagen processing and maturation events, we 
examined the effect of MMP activity on MCAA-induced collagen deposition. Addition of 
EDTA (5 mM) to our cell culture model significantly decreased collagen deposition by cells 
exposed to MCAA +ive sera but did not significantly affect the low levels of collagen 
detected in cells exposed to MCAA −ive sera or NHS. However, MMP inhibition did not 
reduce collagen levels to background, suggesting MMPs act with another collagenolytic 
protein or mechanism to contribute to MCAA-induced collagen deposition. Zymography 
revealed that MMP-8 and MMP-9 are produced by the cultured mesothelial cells and are 
active toward collagen I; however, MMP-9 demonstrated greater activity toward collagen 
compared MMP-8. Reports on the role of MMP-9 in fibrosis development are often 
contradictory, with some evidence supporting a pathogenic role of MMP-9 (Sung et al., 
2005) and others showing that the absence of this protein increases ECM deposition (Oh et 
al., 2002). In our model, MMP-9 is secreted as a zymogen by the cultured mesothelial cell, 
but is activated upon addition of human sera. MMP-9 demonstrated activity toward type I 
collagen, suggesting that it may play a role in ECM remodeling. However, it is unlikely that 
this is a MCAA-specific mechanism of collagen deposition.
Immunoblot analysis of MMPs revealed significantly more MMP-8 protein in supernatants 
of cells exposed to MCAA +ive sera compared to NHS. While incubation with MCAA −ive 
sera also resulted in a non-significant increase in MMP-8, it suggests that another serum 
component may contribute to MMP expression following asbestos exposure. The potential 
involvement of MMP-8 in MCAA-induced collagen deposition is especially intriguing given 
a recent study demonstrating that MMP-8 inactivates the fibrotic cytokine IL-10 via 
cleavage, thus promoting fibrosis development (Garcia-Prieto et al., 2010). A potential in 
vivo role of the observed MMP-8 increase following MCAA exposure could include 
deactivation of local IL-10, thus promoting fibrosis development within the pleural cavity. 
Serve et al. Page 11













Future studies are planned to more closely examine the potential role of MMPs in MCAA-
induced collagen deposition.
Conclusions
The ability of MCAA binding to induce extracellular collagen I deposition suggests a 
potential role of these autoantibodies in contributing to the development of asbestos-
associated pleural fibrosis. Interestingly, mesothelial cells are not often reported as key 
cellular contributors to fibrosis, but our results presented here suggest that they may play a 
more important role than has previously been considered. Additionally, our results suggest 
that MCAAs induce collagen production in the absence of a mesenchymal transition, thus 
suggesting a novel mechanism by which autoantibodies may augment fibrotic disease 
development or progression. Correlative data further support the role for MCAAs in pleural 
disease development or progression (Marchand et al., 2012) with these data supported by 
clinical observations that patients presenting with symptoms of both pulmonary and 
autoimmune disease often progress rapidly to severe pleural and/or interstitial lung disease 
[personal communication, Dr Brad Black, CARD clinic, Libby, Montana]. One goal of on-
going research centered on an LA-exposed cohort is to examine the association of 
autoimmune disease and apparent “rapid progression” of pulmonary disease. MCAA 
presence will be included in this study in order to better understand how MCAA presence 
affects disease progression or, alternatively, if MCAA presence might be a useful diagnostic 
marker of impending pleural fibrosis. By perpetuating pro-fibrosis behavior beyond any 
scarring initially caused by the asbestos itself, it is expected that these autoantibodies could 
promote the non-resolution and active progression of scarring observed in pleural fibrosis.
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Binding of serum antibodies to human mesothelial cells indicates the presence of 
mesothelial cell autoantibodies (MCAAs) as determined by cell-based ELISA as previously 
described (Marchand et al., 2012). (A) Binding by MCCA +ive samples was significantly 
higher compared to the MCAA −ive samples, though no differences were seen in MCAA 
binding of individual serum samples compared pooled sera. Mean ±SE, n =at least 6, p 
=0.002. (B) Binding in pooled sera samples previously identified as MCAA +ive was 
significantly higher than pooled samples of MCAA −ive sera. MCAAs were not detected in 
normal human sera (NHS) obtained from subjects with no known asbestos exposure. 
Removal of IgG by Protein G precipitation (cleared serum) resulted in loss of MCAA 
binding compared to NHS, p =0.001. Mean ±SE, n =6, *p<0.001 by one-way ANOVA.
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MCAAs induced deposition of extracellular type I collagen proteins. (A) Collagen detection 
significantly increased following exposure to MCAA +ive sera compared to MCAA −ive 
sera or NHS. Clearance of IgG reduced collagen detection to background levels. Mean ±SE, 
n =8, *p<0.001 by one-way ANOVA. Collagen deposition by MeT5A cells was determined 
using cell-based ELISA following a 4-day incubation of cells with human sera. (B) No 
significant differences in collagen detection were observed when cells were exposed to 
pooled MCAA +ive sera compared to individual samples, but cell exposure to both pooled 
and individual MCAA +ive samples significantly increased collagen compared to respective 
MCAA −ive samples. Mean ± SD, n =3, p<0.05 by one-way ANOVA with Tukey post hoc 
test.
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MCAA exposure does not induce a mesenchymal transition in cultured human pleural 
mesothelial cells. (A) SMA expression was measured in cells exposed to human sera or 
TGF-β (5 ng) as a positive control for 4 days. Cells were fixed and stained with primary 
anti-SMA and secondary FITC conjugated antibodies and mean fluorescence measured by 
flow cytometry. TGF-β ( ) induced SMA expression compared with exposure to 
secondary antibody control ( , ), MCAA +ive ( , ), or MCAA −ive ( ) sera. 
Exposure to MCAA +ive or −ive sera resulted in increased SMA expression over secondary 
control (x-axis) but expression did not increase to the same degree as TGF-β exposure. TGF-
β was detected in MCAA +ive and −ive sera (B) and supernatants (C) of cells exposed to 
these sera samples. TGF-β was detected using a cytokine bead array analysis and 
concentrations suggest that the TGF-β detected in supernatants was added upon addition of 
sera and not produced by the mesothelial cells, mean ± SD, n =3). (D) Total soluble collagen 
concentrations in cell supernatants were determined using a Sircol Soluble Collagen Assay. 
Incubation with sera from asbestos-exposed subjects did not significantly affect soluble 
collagen compared to NHS.
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SPARC expressed by human mesothelial cells associates with extracellular matrix but does 
not contribute to matrix formation. (A) Immunoblot analysis was used to detect endogenous 
SPARC in lysates of MeT5A cells incubated with human sera. (B) Densitometry analysis 
using Image J software revealed no differences in expression levels between cells exposed to 
MCAA +ive sera or controls, mean ±SD, n =2. (C) Using a cell-based ELISA, detection of 
SPARC increased significantly in MeT5A cells exposed to MCAA +ive sera compared to 
controls, mean ±SE, n =4, *p<0.001 as determined by one-way ANOVA. Cells were 
incubated with human sera for 4 days and SPARC detected using a rabbit polyclonal IgG 
anti-SPARC, H-90 antibody. (D) Addition of anti-SPARC antibody ( ) did not significantly 
alter detection of collagen proteins compared to no treatment (■), indicating that SPARC 
does not directly affect MCAA-induced collagen deposition, as determined by two-way 
ANOVA, mean ±SE, n =4.
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MCAA-induced collagen deposition is dependent on MMP activity. (A) Cell-based ELISA 
was used to detect extracellular collagen deposited by MeT5A cells exposed to human sera 
for 4 days in the absence (■) or presence ( ) of the non-specific MMP inhibitor EDTA (5 
mM). Collagen deposition was significantly inhibited by EDTA in cells exposed to MCAA 
+ive sera (*p =0.018) but not to NHS (p =0.28) or MCAA −ive sera (p =0.32) as determined 
by two-way ANOVA. (B) Collagen zymography revealed the presence of MMP-8 and 
MMP-9 in supernatants of cells exposed to human sera for 4 days. MMPs were identified by 
their reported molecular weights and bacterial collagenase (200 pg) was used as a positive 
control. (C) Immunoblot analysis of MMP-8 confirmed its identity. (D) Densitometry 
analysis of the immunoblot revealed significantly more MMP-8 present in supernatants of 
cells exposed to MCAA +ive sera compared to NHS. However, exposure to MCAA −ive 
sera also resulted in increased MMP-8, although this increase was not significant compared 
to NHS. Statistical significance is indicated by different letters at p<0.01 by one-way 
ANOVA, mean ±SD, n =3.
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